Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Therapy in Elderly Advanced NSCLC
NCT01850303Phase 3Completed
- Sponsor
- IFCT
- Start
- May 2013
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Overall Survival at 15 months. Started May 2013; status: completed.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01850303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850303.